Mar 3 2023 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101889 | Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial |
| 10% higher mortality (p=0.81). RCT severe COVID-19 patients showing no significant difference in outcomes with razuprotafib. | ||
Feb 26 2021 |
et al., NCT04511650 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 |
| 178% higher progression (p=0.37) and 469% lower hospital discharge (p=0.28). RCT 29 patients showing no significant differences with razuprotafib treatment. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.